Fortrea Holdings Inc. (FTRE)
(Real Time Quote from BATS)
$23.02 USD
-0.18 (-0.78%)
Updated Jul 10, 2024 01:32 PM ET
3-Hold of 5 3
B Value F Growth C Momentum D VGM
Fortrea Holdings Inc. (FTRE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$31.55 | $40.00 | $27.00 | 35.99% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Fortrea Holdings Inc. comes to $31.55. The forecasts range from a low of $27.00 to a high of $40.00. The average price target represents an increase of 35.99% from the last closing price of $23.20.
Analyst Price Targets (10)
Broker Rating
Fortrea Holdings Inc. currently has an average brokerage recommendation (ABR) of 2.18 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 2.18 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, five are Strong Buy, representing 45.45% of all recommendations. A month ago, Strong Buy represented 45.45%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 5 | 2 | 3 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.18 | 2.18 | 2.18 | 1.88 | 2.13 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/6/2024 | Goldman Sachs | Matthew Sykes | Not Available | Hold |
5/28/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Not Available | Hold |
5/14/2024 | Robert W. Baird & Co. | Eric W Coldwell | Hold | Strong Buy |
5/14/2024 | Evercore Partners | Elizabeth Anderson | Strong Buy | Strong Buy |
1/25/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1/5/2024 | William Blair | Maxwell A Smock | Not Available | Hold |
1/4/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
12/11/2023 | Not Identified | Not Identified | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.18 |
ABR (Last week) | 2.18 |
# of Recs in ABR | 11 |
Average Target Price | $31.55 |
LT Growth Rate | 15.40% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 68 of 252 |
Current Quarter EPS Est: | 0.08 |